Therapeutics News and Research

RSS

Chelsea Therapeutics announces financial results for fourth quarter 2009

Chelsea Therapeutics International, Ltd. reported financial results for the fourth quarter and full year 2009 and will host a conference call this afternoon at 4:30 PM ET to discuss these results and provide a quarterly update on the Company's development progress.

11 Mar 2010

Bayer's bioequivalence study comparing Adalat XL to Mylan-Nifedipine Extended Release flawed, says Mylan

Mylan today reported that it has identified multiple flaws within a purported bioequivalence study sponsored by Bayer Inc. of Canada. The study compared Bayer's antihypertensive Adalat(R) XL(R) tablets, 60 mg, marketed in Canada, to Mylan's approved generic version, Mylan-Nifedipine Extended Release tablets, 60 mg, marketed in Canada.

10 Mar 2010

Alison Walker selected to receive ASH-AMFDP Award

Alison Walker, MD, has been selected to receive the ASH-AMFDP Award, and will begin her research in acute myeloid leukemia in July of this year. The award, designed to help increase the number of underrepresented minority scholars in the field of hematology, is the result of a partnership between the American Society of Hematology and the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation.

10 Mar 2010

Papaya's anticancer effect against broad range of lab-grown tumors documented

The humble papaya is gaining credibility in Western medicine for anticancer powers that folk cultures have recognized for generations.

10 Mar 2010

AMT initiates dosing in Phase I/II gene therapy clinical trial for hemophilia B

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the first patient has been dosed in the Phase I/II exploratory clinical trial with a gene therapy product for hemophilia B, a seriously debilitating and potentially lethal disease.

10 Mar 2010

Cellectar completes enrollment in (131)I-CLR1404 Phase I dosimetry trial for advanced solid malignancies

Cellectar, Inc., a privately held radiopharmaceutical company that designs and develops products to detect, treat and monitor human cancers, today announced that enrollment for its Phase I dosimetry trial for its lead drug candidate, (131)I-CLR1404 has been completed. Results of this trial will be used to set the starting dose in a follow-on Phase I dose escalation study planned for later this year. Institutions that participated in the trial include City of Hope, Duke University Medical Center, Georgetown University/Lombardi Cancer Center, and Johns Hopkins Hospital.

10 Mar 2010

Celltrion develops novel human monoclonal antibodies against influenza virus infection

Celltrion, Inc., a South Korean biopharmaceutical company, has developed novel human monoclonal antibodies against influenza virus infection, which neutralize a broad spectrum of influenza viruses, including pandemic H1N1 and the deadly H5N1 avian influenza virus. Preliminary tests in laboratory animals indicate that the novel human monoclonal antibodies can be used to prevent disease when given either before or after infection.

10 Mar 2010

Researchers in Canada discover novel oncolytic viral therapy against prostate cancer

Researchers in Canada have detected a novel oncolytic viral therapy against prostate cancer with use of a virus called the reovirus, according to study results published in Cancer Research, a journal of the American Association for Cancer Research.

10 Mar 2010

Chimerix initiates CMX001 Phase 2 clinical trial in stem cell transplant patients for CMV

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the initiation of a multi-center Phase 2 clinical trial designed to evaluate CMX001 in stem cell transplant recipients who are seropositive for cytomegalovirus (CMV).

9 Mar 2010

Orexigen Therapeutics reports net loss of $15.0M for three months ended December 31, 2009

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the three months and year ended December 31, 2009.

9 Mar 2010

MicroConstants acquires access to new nanosizing technology

MicroConstants, a GLP-compliant Contract Research Organization specializing in bioanalytical and pharmacokinetic analysis, has acquired access to a new nanosizing technology that transforms water insoluble compounds into nanoparticles, making formulation preparation and dosing for toxicology studies easier.

9 Mar 2010

Harvard University, Dana-Farber Cancer Institute complete major licensing agreement with Acetylon

Harvard University and Dana-Farber Cancer Institute announced today that they have concluded a major licensing agreement with Acetylon under which Harvard and Dana-Farber granted an exclusive therapeutic license to a robust platform technology and chemical methodology that enables high-throughput screening and lead optimization for HDAC inhibitor compounds.

9 Mar 2010

RepRegen's Strontium-based bioactive glass platform encourages osteoblast cell activity and proliferation

RepRegen™, the ‘smart biomaterials’ company previously known as BioCeramic Therapeutics, announced today that data from an in vitro study has demonstrated that its patented Strontium-based bioactive glass platform promotes osteoblast cell activity and proliferation. If in vivo studies, which are currently underway, demonstrate similar results, then RepRegen believes its platform has the potential to significantly improve the repair and regeneration of hard-tissue, such as bone.

9 Mar 2010

Positive results from INSYS Therapeutics' phase III trial for Fentanyl SL Spray

INSYS Therapeutics, Inc. announces positive results from the pivotal phase III efficacy trial for patients utilizing the Fentanyl Sublingual Spray technology to treat breakthrough cancer pain. All primary and secondary endpoints were achieved in the study, and the drug is the first product to ever show statistically significant pain relief when measuring the summary of pain intensity difference at five minutes in a phase III breakthrough cancer pain trial using Fentanyl.

9 Mar 2010

GTA's stockholders voted to approve merger between GTA and Pernix Therapeutics

Golf Trust of America, Inc. announced that GTA's stockholders voted to approve the four proposals that were conditions to closing the previously-announced merger between GTA and Pernix Therapeutics, Inc. at a Special Meeting of Stockholders held earlier today.

8 Mar 2010

Rexahn Pharmaceuticals granted Japanese patent for Archexin

Rexahn Pharmaceuticals, Inc, a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the Japanese Patent Office has issued a patent for its novel anti-cancer compound, Archexin®.

8 Mar 2010

Positive Phase 2 data from Nektar Therapeutics' NKTR-102 study in women with platinum-resistant ovarian cancer

Nektar Therapeutics today announced preliminary progression-free survival data from the first stage of a two-stage Phase 2 clinical study evaluating single-agent treatment with NKTR-102 in women with platinum-resistant ovarian cancer. In the first stage of the study, 39 patients were enrolled with platinum-resistant disease and were evaluable for the secondary endpoint of progression-free survival (PFS).

8 Mar 2010

Positive data from Argos Therapeutics' AGS-003 Phase 2 trial for mRCC

Argos Therapeutics today announced the presentation of positive data from a Phase 2 trial that evaluated the safety, clinical response and immune response of AGS-003 treatment in newly diagnosed patients with metastatic renal cell carcinoma (mRCC). The data were discussed March 7 in a poster presentation at the ASCO Genitourinary Cancers Symposium.

8 Mar 2010

MS Awareness Week: Time for nation to go orange and move it to end MS

MS Awareness Week March 8-14 is the time for the nation to go orange and move it to end multiple sclerosis, a disease where someone is newly diagnosed every hour of every day. Supported by a Congressional resolution, this year MS Awareness Week and the state of MS research aptly coincide. Move it to create a world free of MS!

8 Mar 2010

Sigma Life Science extends portfolio of knockout rat models with the release of ADME/Tox applications

Sigma® Life Science, an innovative brand of Sigma-Aldrich®, today extended its portfolio of knockout rat models with the announcement of a new suite of models designed to facilitate more predictive absorption, distribution, metabolism, excretion and toxicity (ADME/Tox) studies.

8 Mar 2010

Therapeutics News and Research

Chelsea Therapeutics announces financial results for fourth quarter 2009

Bayer's bioequivalence study comparing Adalat XL to Mylan-Nifedipine Extended Release flawed, says Mylan

Alison Walker selected to receive ASH-AMFDP Award

Papaya's anticancer effect against broad range of lab-grown tumors documented

AMT initiates dosing in Phase I/II gene therapy clinical trial for hemophilia B

Cellectar completes enrollment in (131)I-CLR1404 Phase I dosimetry trial for advanced solid malignancies

Celltrion develops novel human monoclonal antibodies against influenza virus infection

Researchers in Canada discover novel oncolytic viral therapy against prostate cancer

Chimerix initiates CMX001 Phase 2 clinical trial in stem cell transplant patients for CMV

Orexigen Therapeutics reports net loss of $15.0M for three months ended December 31, 2009

MicroConstants acquires access to new nanosizing technology

Harvard University, Dana-Farber Cancer Institute complete major licensing agreement with Acetylon

RepRegen's Strontium-based bioactive glass platform encourages osteoblast cell activity and proliferation

Positive results from INSYS Therapeutics' phase III trial for Fentanyl SL Spray

GTA's stockholders voted to approve merger between GTA and Pernix Therapeutics

Rexahn Pharmaceuticals granted Japanese patent for Archexin

Positive Phase 2 data from Nektar Therapeutics' NKTR-102 study in women with platinum-resistant ovarian cancer

Positive data from Argos Therapeutics' AGS-003 Phase 2 trial for mRCC

MS Awareness Week: Time for nation to go orange and move it to end MS

Sigma Life Science extends portfolio of knockout rat models with the release of ADME/Tox applications

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News